体軸性脊椎関節炎市場：KOLの洞察

当レポートでは、体軸性脊椎関節炎（axSpA）治療の現状と今後の方向性について、生物学的製剤とパイプライン治療の使用に焦点を当てて詳細に分析しています。非ステロイド性抗炎症薬（NSAIDs）に続く第一選択薬としての抗腫瘍壊死因子（TNF）阻害薬の使用、コセンティクス、タルツ、ビムゼレックスなどのインターロイキン-17（IL-17）阻害薬の位置づけ、ゼルヤンツやリンボックのようなヤヌスキナーゼ（JAK）阻害薬の慎重な使用について検証しています。axSpA管理における現在の治療戦略と新たな動向の包括的な概観を得ることができます。

レポートの内容

• axSpA治療において抗TNFは現在どのように使用されているか
• 抗TNFバイオシミラー製剤はaxSpA治療にどのような影響を与えているか
• コセンティクス、タルツ、ビムゼレックスなどのIL-17阻害薬は、治療アルゴリズムにおいてどのような位置づけにあるか
• 長期試験はIL-17の処方動向にどのような影響を与えたか
• リンボックやゼルヤンツなどのJAK阻害薬は、axSpA治療のパラダイムにおいてどのような位置づけにあるのか
• ORALサーベイランス試験はJAK阻害薬の処方に影響を与えたか
• JyselecaはaxSpA市場において可能性があるのか、また何を示さなければならないのか
• axSpAの診断と治療における現在のアンメットニーズ
• 今後3～5年間で、axSpAの治療アルゴリズムはどのように進化するか

主要ブランド

This report provides an in-depth analysis of the current landscape and future directions in the treatment of axial spondyloarthritis (axSpA), focusing on the use of biologic and pipeline therapies. It examines the use of anti-tumour necrosis factor (TNF) inhibitors as the first-line treatment following non-steroidal anti-inflammatory drugs (NSAIDs), the positioning of interleukin-17 (IL-17) inhibitors, such as Cosentyx, Taltz, and Bimzelx, and the cautious use of Janus kinase (JAK) inhibitors like Xeljanz and Rinvoq. Gain a comprehensive overview of current treatment strategies and emerging trends in axSpA management.

Key Questions Answered:

• How are anti-TNFs currently used in axSpA treatment lines?
• What impact have anti-TNF biosimilars had on axSpA treatment?
• How are IL-17 inhibitors like Cosentyx, Taltz, and Bimzelx positioned in treatment algorithm?
• How have long-term trials influenced IL-17 prescription trends?
• Where do JAK inhibitors like Rinvoq and Xeljanz fit in the axSpA treatment paradigm?
• Has the ORAL Surveillance study affected JAK inhibitor prescriptions?
• Does Jyseleca have potential in the axSpA market, and what must it demonstrate?
• What are the current unmet needs in axSpA diagnosis and treatment?
• How will the axSpA treatment algorithm evolve over the next three to five years?

Key Brands:

Partial List of Participating Experts:

• Associate Professor of Medicine, Director of Yale Spondyloarthritis Program and Co-chair, Safety and Quality Council at Yale School of Medicine, CT
• Assistant Professor of Medicine, Brigham and Women's Hospital, MA
• Clinical Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Co-Director of the Division of Rheumatology at Presbyterian Hospital, Dallas, TX
• Director of the Leeds NIHR Biomedical Research Centre, Professor of Rheumatology, University of Leeds, Leeds, UK
• Full Professor of Rheumatology at the Department of Medicine and Health Sciences "Vincenzo Tiberio" and Head of the Internal Medicine and Rheumatology Unit at the University of Molise in Campobasso, Italy
• Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC and Director of the Amsterdam Rheumatology and Immunology Center ARC in Amsterdam, Netherlands

Methodology

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.